ABOUT ESPERO (Espero BioPharma)
We named our company Espero because it means hope. And that’s what we seek to provide everyone who takes our innovative cardiovascular medicines. Hope for improved health and hope for a better tomorrow.
Espero is a biopharmaceutical company focusing on the late-stage development and commercialization of medicines to treat cardiovascular diseases, the leading cause of death worldwide. Recently, Espero merged with Armetheon, Inc., a privately-held, specialty pharmaceutical company developing innovative medicines, initially in thrombosis (tecarfarin) and cardiac arrhythmias (budiodarone). The Company also markets and distributes three in-market standard of care cardiovascular drugs: GoNitroTM (nitroglycerin) sublingual powder (antianginal), Durlaza® (aspirin) Extended Release Capsules, and Nitrolingual® Pumpspray (antianginal).
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial FibrillationMarch 11, 2019
Espero BioPharma to Present at BIO CEO & Investor conference on February 11, 2019February 7, 2019
Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in ChinaJanuary 24, 2019
Espero Biopharma’s late-clinical stage oral anticoagulant candidate – Tecarfarin – addresses a major unmet need – a medication with potentially fewer adverse and fatal drug reactions and expected compatibility with treatment plans for patients with prosthetic heart valves.
Espero BioPharma is exploring its portfolio of small molecules as therapies to treat cardiac arrhythmias, with particular interest in atrial fibrillation and ventricular tachycardias and fibrillation. An arrhythmia can occur in either chamber of the heart, atrium or ventricle, and is due to abnormal electrical signals. When arrhythmias result in disabling symptoms or a device firing, efforts to prevent future arrhythmia episodes may include ablative therapy or drug therapy. Ablation is of limited success, often temporary, and is often augmented with drug therapy.
Educating the Community
As we advance the clinical stages of testing for tecarfarin and budiodarone, we are sharing our story with healthcare providers at appropriate peer-reviewed forums.
Learn More Today
As we complete the late clinical stage for Tecarfarin, we’d like to share our story with healthcare providers. Physicians and their patients could benefit from Espero Biopharma’s novel drug development approach. Please contact us for more information.